- Home
- GLOB vs AXSM Comparison
GLOB vs AXSM Comparison
Compare GLOB & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLOB
- AXSM
- Stock Information
- Founded
- GLOB 2003
- AXSM 2012
- Country
- GLOB Luxembourg
- AXSM United States
- Employees
- GLOB N/A
- AXSM N/A
- Industry
- GLOB EDP Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GLOB Technology
- AXSM Health Care
- Exchange
- GLOB Nasdaq
- AXSM Nasdaq
- Market Cap
- GLOB 4.7B
- AXSM 5.1B
- IPO Year
- GLOB 2014
- AXSM 2015
- Fundamental
- Price
- GLOB $92.76
- AXSM $112.35
- Analyst Decision
- GLOB Buy
- AXSM Strong Buy
- Analyst Count
- GLOB 16
- AXSM 17
- Target Price
- GLOB $174.94
- AXSM $171.65
- AVG Volume (30 Days)
- GLOB 1.0M
- AXSM 613.7K
- Earning Date
- GLOB 08-14-2025
- AXSM 08-04-2025
- Dividend Yield
- GLOB N/A
- AXSM N/A
- EPS Growth
- GLOB N/A
- AXSM N/A
- EPS
- GLOB 3.38
- AXSM N/A
- Revenue
- GLOB $2,455,696,000.00
- AXSM $432,157,000.00
- Revenue This Year
- GLOB $4.36
- AXSM $62.84
- Revenue Next Year
- GLOB $6.03
- AXSM $60.02
- P/E Ratio
- GLOB $27.51
- AXSM N/A
- Revenue Growth
- GLOB 11.90
- AXSM 72.16
- 52 Week Low
- GLOB $86.02
- AXSM $72.21
- 52 Week High
- GLOB $238.32
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- GLOB 44.38
- AXSM 65.29
- Support Level
- GLOB $89.74
- AXSM $102.26
- Resistance Level
- GLOB $94.59
- AXSM $106.35
- Average True Range (ATR)
- GLOB 3.12
- AXSM 3.59
- MACD
- GLOB 0.98
- AXSM 0.98
- Stochastic Oscillator
- GLOB 72.94
- AXSM 84.48
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.